Clarivate Analytics launched its annual “Drugs to Watch” report, identifying 12 new drugs forecast to achieve annual sales of $1 billion or more (i.e., blockbuster status) by 2022 using the Cortellis database, which includes information gathered from diverse sources including drug pipelines, patents, clinical trials, chemistry, deals, and company announcements. More blockbuster drugs have been predicted to launch in…